CURE Epilepsy has raised more than $60 million to fund epilepsy research. We talk with Dr Laura Lubbers about the work CURE Epilepsy is doing.
Working collaboratively has been one of the hallmarks of Prof Daniel Lowenstein’s career and has led to breakthrough research.
We talk with Dr Kiran Reddy about the plans for the RC-222 treatment program with the goal of developing a treatment for SCN2A gain-of-function epilepsies.
When Alex Nemiroff’s son was born, he was determined to work towards finding treatments for SCN2A, and is now CEO of RogCon with a treatment in development.
Natural History Studies (NHS) are important in planning trials of treatment. We talk with Dr Katherine Howell, principal investigator of the SCN2A NHS.
Prof Ingrid Scheffer has published many key papers in SCN2A and genetic epilepsies and discusses the progress that has been made in understanding SCN2A.
Listen to SCN2A Insights to keep up to date with the latest research in SCN2A, genetic epilepsy and rare genetic disorders.
The following work from Assistant Prof. Kevin Benders lab was presented on the 20th of October in Chicago, at Neuroscience 2019 held by Society for
The SCN2A International Natural History Study (NHS) is comprised of clinicians collaborating from multiple academic institutions, including US, European and Australian based clinicians. Dr. Katherine
Today we are introducing the SCN2A research team at the Florey Institute. The team is lead by Prof Steven Petrou, Director of Florey Institute. The
Happy Australia Day! Today we launch SCN2A Australia. We look forward to working with families, researchers, clinicians and professional bodies to improve the lives of
Genetic Epilepsy Family Conference 2021 run by GETA
www.eventbrite.com.au
In 2021 GETA will hold a hybrid event - with those who can and want to attend can do so face to face at the The Florey Institute.
© All rights reserved. SCN2A Australia | Privacy Policy
